Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

New Diabetes Therapeutics to Steal Ground from Insulin Therapies

By Oliver Mundell, Healthcare Analyst, GBI Research | October 25, 2017

The incidence of diabetes mellitus (DM), and most notably type 2 diabetes mellitus (T2DM), which accounts for 90–95% of all DM cases, is growing rapidly on a global scale, according to business intelligence provider GBI Research.

The company’s latest report: ‘Global Diabetes Drugs Market to 2023 – A Diversifying Treatment Landscape as GLP-1 Receptor Agonists and SGLT-2 Inhibitors Gain Ground Following Landmark Cardiac Outcomes’reveals that the US is expected to experience the greatest rise in T2DM prevalence, and incidence rates are also expected to increase from 2.5% in 2016 to 4% by 2023.

Diabetes mellitus (DM) is a generalized term used to define multiple diseases with different etiologies that are characterized by chronic hyperglycemia (high blood glucose levels) resulting from insufficient synthesis, secretion or signaling of insulin – a hormone produced by the pancreas. The main role of insulin is to facilitate the absorption of glucose into skeletal muscle and fat cells following food digestion, which provides these cells with a source of energy for metabolism, and also reduces the concentration of glucose in the blood. Insulin signaling also has important roles in many processes including growth, development and controlling inflammation.

The DM market has undergone a dynamic shift over the past decade, primarily due to the entry of three new non-insulin drug classes for T2DM: glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors and sodium–glucose linked transporter 2 (SGLT-2) inhibitors. Increased market diversification is expected to continue throughout the forecast period due to patent expiries for major insulin products and increased uptake of non-insulin drugs.

Oliver Mundell, Healthcare Analyst at GBI Research, commented: ‘In 2016, the top five products, all of which are insulin products, commanded 47% of the market by sales. By 2023 the top 10 products are expected to occupy 42% market share, many of which will be non-insulin products.’

Alongside rising prevalence, market diversification will be a key driver of growth, with the DM market projected to increase from $97.4 billion in 2016 to $158.8 billion in 2023, at a Compound Annual Growth Rate (CAGR) of 7.2%.

Mundell continued: ‘Competition will intensify over the forecast period as more companies enter the DM market space. However, Novo Nordisk, which is currently the leading player in terms of market share, is expected to maintain its position throughout the forecast period.

Despite declining revenues for high-grossing products such as Levemir (insulin detemir), more recent market additions such as Tresiba (insulin degludec), as well as the upcoming pipeline products semaglutide and oral semaglutide, are expected to more than compensate.

Mundell added: ‘The development of extremely long release insulin products and a fully artificial pancreas using both insulin and glucagon will shape the future of the DM market beyond the forecast period as ease of administration and safety is increased.’

Related Articles Read More >

2025 R&D layoffs tracker hits 132,075 as Amazon CEO signals AI will cut more jobs
Probiotics power a bioresorbable battery that can run from 4 to 100+ minutes
Health-related innovation in Morocco highlighted by resident inventor patenting activity
ARPA-H funds $29M Ginkgo-led project to reshore pharma supply chains using wheat germ tech
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE